HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Outcome of intraarterial urokinase for acute vascular occlusion.

Abstract
Intraarterial urokinase (IAUK) was administered to 33 patients on 40 occasions for the treatment of acute extremity ischemia and long-term patency was assessed. Lysis was successful in 39 of the 40 cases (95%). Occlusive thrombus was cleared in 12 of 13 patients with native artery occlusion (7 complete, 5 partial), 8 of 9 with autologous vein grafts (5 complete, 3 partial), and in all 18 patients with synthetic grafts (17 complete, 1 partial). The primary cumulative patency following successful IAUK was 100% for native arteries and 47% for synthetic grafts at 12 months, and 23% for autologous grafts at 9 months. The difference in rethrombosis rate between autologous vein (67%) and native artery (0%) was significant (p = 0.02) as was the difference between infrainguinal prosthetic grafts (63%) and native artery (p = 0.025). IAUK is most effective for the treatment of native artery occlusion, but is significantly less effective for thrombosed infrainguinal autologous vein or synthetic grafts due to the likelihood of reocclusion, despite the high immediate success rate. For autologous vein grafts, lysis is frequently incomplete and patency rapidly deteriorates regardless of adjunctive therapy to relieve the underlying obstruction.
AuthorsF N Parent 3rd, J J Piotrowski, V M Bernhard, G D Pond, T S Pabst 3rd, D A Bull, G C Hunter, K E McIntyre
JournalThe Journal of cardiovascular surgery (J Cardiovasc Surg (Torino)) 1991 Sep-Oct Vol. 32 Issue 5 Pg. 680-9 ISSN: 0021-9509 [Print] Italy
PMID1939333 (Publication Type: Journal Article)
Chemical References
  • Urokinase-Type Plasminogen Activator
Topics
  • Blood Vessel Prosthesis
  • Female
  • Graft Occlusion, Vascular (drug therapy, epidemiology)
  • Humans
  • Infusions, Intra-Arterial
  • Leg (blood supply)
  • Life Tables
  • Male
  • Middle Aged
  • Recurrence
  • Retrospective Studies
  • Thrombolytic Therapy
  • Thrombosis (drug therapy, epidemiology)
  • Urokinase-Type Plasminogen Activator (therapeutic use)
  • Vascular Patency

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: